Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03672396
Other study ID # LCCC1613
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 1, 2017
Est. completion date December 31, 2019

Study information

Verified date December 2020
Source UNC Lineberger Comprehensive Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This single arm, multi-site pilot study aims to evaluate the feasibility of recruiting and adherence to a 12 week home-based exercise intervention to be conducted in men with metastatic castration resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Thirty patients will be enrolled, with the expectation that 20-25 will complete all follow-up measures.


Description:

The purpose of this trial is to evaluate the feasibility and adherence to a home-based 12 week exercise intervention in mCRPC patients receiving ADT. It will also examine if a home-based exercise intervention can improve muscle strength, body composition, physical function, cardiopulmonary function fatigue, and patient reported outcomes (fatigue, depression, quality of life (QoL)).


Recruitment information / eligibility

Status Completed
Enrollment 22
Est. completion date December 31, 2019
Est. primary completion date December 31, 2019
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: - Metastatic disease that has progressed despite castrate levels of testosterone (surgically or medically castrated, with testosterone levels of < 50 ng/dL) receiving ADT. This will be verified by assessing total testosterone levels within 4 weeks prior to enrollment. - No current chemotherapy. - Patients may be receiving additional hormonal therapy agents including but not limited to antiandrogens (e.g. bicalutamide, enzalutamide) and CYP17 inhibitors (e.g. abiraterone). - Ability to engage safely in moderate exercise as determined by their treating physician. - Not previously engaged in regular exercise training (<3 or more d/wk for > 30 min/d or <90 mins per week total including strength training, aerobic training, or walking) in the past 6 months. - Access to a computer or a smart phone for syncing and uploading wearable activity data. - Be able to speak and read English. Exclusion Criteria: - Any condition that causes severe pain with exertion. - History of bone fractures. - Active cardiovascular disease including any of the following: - New York Heart Association (NYHA) Grade II or greater congestive heart failure . - History of myocardial infarction or unstable angina within 6 months prior to Day 1. - History of stroke or transient ischemic attack within 6 months prior to Day 1. - Acute or chronic respiratory disease that is severe enough to compromise the ability of the participant to safely engage in exercise training protocol. - Acute or chronic bone/joint/muscular abnormalities compromising their ability to exercise. - Neurological conditions that affect balance and, or muscle strength. - Dementia, altered mental status or any psychiatric condition prohibiting the understanding or rendering of informed consent.

Study Design


Intervention

Behavioral:
Home-based exercise
The intervention consists of aerobic and strength training ~3 times per week for 12 weeks with each session lasting 1 hour. The progressive aerobic exercise will involve walking that varies from from 15 to 30 minutes done 2-4 times per week at an intensity from 40% to 65% of heart rate reserve. Therabands elastic bands will be used to perform 12 to 15 repetitions per exercise. Once a participant can comfortably complete 15 repetitions for all prescribed sets, they will increase resistance by moving up to the next band. The training volume increased from 1 set per exercise on week 1 to 3 sets by week 12.

Locations

Country Name City State
United States Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill Chapel Hill North Carolina
United States Comprehensive Cancer Center, Wake Forest Baptist Health Winston-Salem North Carolina

Sponsors (2)

Lead Sponsor Collaborator
UNC Lineberger Comprehensive Cancer Center Wake Forest University Health Sciences

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Patients Who Complete the Pre/Post Exercise Intervention Testing. To estimate the feasibility of a 12 week, home-based exercise intervention in metastatic castrate resistant prostate cancer (mCPRC) patients undergoing androgen deprivation therapy by reporting the percentage of patients who complete the pre/post testing following the intervention.
This was calculated as the number of subjects who completed the trial compared to the total number who completed baseline testing.
12 weeks after baseline testing
Secondary Adherence to the Intervention To report the level of adherence to the exercise intervention in patients completing pre/post testing. Successful adherence to the program is completion of 75% of all prescribed exercise and will be assessed using wearable technology to track walking and exercise logs to track resistance training adherence.
Adherence was determined as the number of exercise sessions attempted/completed over the total number of session prescribed.
12 weeks after baseline testing
Secondary Physical Function: 6m Walk The time to complete (in sec) the 6m rapid walk test will be performed. 12 weeks after baseline testing
Secondary Physical Function: Timed Up and Go The time to complete (in sec) the 2.44m (8 ft) timed up and go test will be performed as an indicator of agility, balance, and physical function. A lower total time is indicative of greater performance. 12 weeks after baseline testing
Secondary Physical Function: Stair Climb The time to climb a flight of stairs (in sec) will be performed as an indicator of functional strength, muscle power, and balance. A lower total time (and higher calculated power output) is indicative of greater performance. 12 weeks after baseline testing
Secondary Physical Function: 400m Walk The time to walk 400m (in sec) will be performed as an indicator of walking endurance and gait speed will be determined. A lower total time and higher gait speed indicates greater cardiorespiratory capacity and will be correlated with cardiopulmonary function scores (outcome 14). 12 weeks after baseline testing
Secondary Patient Reported Outcomes: Fatigue Fatigue will be measure using the Functional Assessment of Chronic Illness Therapy Fatigue, a 1 page form that uses a rating scale that goes from 0 to 52. It assesses the patient's fatigue levels in the last 7 days. It also measures how usual activities, performing work, walking, relationship, and enjoyment of life are affected by fatigue. A higher score indicates higher quality of life (and lower fatigue). 12 weeks after baseline testing
Secondary Patient Reported Outcomes: Quality of Life Quality of life will be measured using the Functional Assessment of Cancer Therapy-Prostate (FACT-P). The FACT-P is composed of both multi-item scales and single-item measures. These include physical, social, emotional, and functional well-being, along with an assessment of prostate-specific health status. five functional scales, three symptom scales, a global health status / QoL scale, and six single items. All of the individual questions are scored from 0-4 with total scores ranging between 0 and 156 where a higher number represents higher QoL. 12 weeks after baseline testing
Secondary Patient Reported Outcomes: Depression Depression will be measured using the Hospital Anxiety and Depression Scale, a concise, self-administered 1 page form that categorizes anxiety and depression. The total score goes from 0-21, and scores are categorized from minimal to severe depression/anxiety. Higher total scores indicate greater levels of depression. 12 weeks after baseline testing
Secondary Patient Reported Outcomes: Anxiety Depression will be measured using the Hospital Anxiety and Depression Scale, a concise, self-administered 1 page form that categorizes anxiety and depression. The total score goes from 0-21, and scores are categorized from minimal to severe depression/anxiety. Higher total scores indicate greater levels of depression. 12 weeks after baseline testing
Secondary Muscle Size (Cross-sectional Area) Muscle size will be analyzed using ultrasound of the vastus lateralis of the dominant leg. All assessments will be completed before and after the intervention to determine the muscle size. Higher muscle mass and quality are associated with greater muscle strength, physical function, QoL, and mortality. 12 weeks after baseline testing
Secondary Muscle Quality Muscle architecture will be analyzed using ultrasound of the vastus lateralis of the dominant leg. All assessments will be completed before and after the intervention to determine the muscle quality. Higher muscle mass and quality are associated with greater muscle strength, physical function, QoL, and mortality. Muscle quality is reported in arbitrary units, where a lower value indicates a higher/better muscle quality. 12 weeks after baseline testing
Secondary Chest Press Maximal Strength Upper and lower body muscle strength will be assessed using the chest and leg presses. Maximal strength is defined as the highest load (kilograms) that the participant can successfully lift one time. Greater maximal strength is associated with greater physical function and QoL. 12 weeks after baseline testing
Secondary Chest Press Muscle Endurance Upper and lower body muscle endurance will be assessed using the chest and leg presses. Muscle endurance is the total number of repetitions completed using 70% of maximal load determined during muscle strength testing (outcome 12). Greater muscle endurance are associated with greater physical function and QoL. 12 weeks after baseline testing
Secondary Leg Press Maximal Strength Upper and lower body muscle strength will be assessed using the chest and leg presses. Maximal strength is defined as the highest load (kilograms) that the participant can successfully lift one time. Greater maximal strength is associated with greater physical function and QoL. 12 weeks after baseline testing
Secondary Leg Press Muscle Endurance Upper and lower body muscle endurance will be assessed using the chest and leg presses. Muscle endurance is the total number of repetitions completed using 70% of maximal load determined during muscle strength testing (outcome 12). Greater muscle endurance are associated with greater physical function and QoL. 12 weeks after baseline testing
Secondary Cardiopulmonary Function To report changes in cardiopulmonary function following the intervention. Cardiopulmonary function (VO2 peak) will be assessed using a graded exercise test on a treadmill. Patients will begin the test walking slowly on the treadmill and every two minutes, the grade and speed of the treadmill will be increased in a progressive manner until fatigue occurs. Respiratory gases will be collected throughout the test and analyzed using a metabolic cart to determine oxygen utilization and carbon dioxide production. The maximal oxygen uptake that is recorded will be used as a marker of aerobic fitness. 12 weeks after baseline testing
Secondary Lean Mass To report changes in total lean mass following the intervention. Total body lean mass will be measured using dual-energy x-ray absorptiometry (DXA) before and after the intervention. 12 weeks after baseline testing
Secondary Fat Mass To report changes in total fat mass following the intervention. Total fat mass will be measured using dual-energy x-ray absorptiometry (DXA) before and after the intervention. 12 weeks after baseline testing
Secondary Percent Body Fat To report changes in relative fat mass following the intervention. Total body percent fat (percentage of fat mass relative to total mass) will be measured using dual-energy x-ray absorptiometry (DXA) before and after the intervention. 12 weeks after baseline testing
See also
  Status Clinical Trial Phase
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT00974311 - Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy Phase 3
Active, not recruiting NCT03700099 - Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide Phase 2
Completed NCT02124668 - A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy Phase 2
Completed NCT01634061 - Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients Phase 1
Completed NCT01338831 - Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer Phase 1
Terminated NCT03652493 - Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway Phase 2
Recruiting NCT04549207 - Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer Phase 4
Active, not recruiting NCT03305224 - The Combination Therapy With Ra-223 and Enzalutamide Phase 2
Active, not recruiting NCT04090528 - pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer Phase 2
Recruiting NCT04070209 - Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X) Phase 2
Active, not recruiting NCT06193993 - Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients Phase 1
Completed NCT02669771 - Long-Term Specified Drug Use-Results Survey for Xtandi Capsule
Active, not recruiting NCT05084859 - A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors Phase 1
Recruiting NCT03934164 - Molecular Stratification Profiling Protocol in Metastatic Castration Resistant Prostate Cancer (mCRPC) - MAESTRO
Recruiting NCT03506997 - Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer Phase 2
Completed NCT03569280 - Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients Phase 1
Enrolling by invitation NCT03356912 - CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy Phase 2
Not yet recruiting NCT04148885 - A Trial of Paclitaxel (Albumin-binding) for Castration-resistant Prostate Cancer Phase 1/Phase 2